Simulations Plus (NASDAQ:SLP) released its earnings results on Wednesday. The technology company reported $0.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.02, Fidelity Earnings reports. Simulations Plus had a net margin of 24.09% and a return on equity of 23.48%. The company had revenue of $8.03 million for the quarter, compared to the consensus estimate of $7.52 million.
SLP traded up $0.28 during trading on Friday, hitting $34.88. 4,973 shares of the company traded hands, compared to its average volume of 89,822. The firm has a market cap of $585.20 million, a P/E ratio of 72.67 and a beta of -0.34. The stock’s fifty day moving average is $34.16 and its 200 day moving average is $31.77. Simulations Plus has a one year low of $17.18 and a one year high of $41.95.
The business also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 25th were given a dividend of $0.06 per share. The ex-dividend date was Thursday, October 24th. This represents a $0.24 annualized dividend and a yield of 0.69%. Simulations Plus’s payout ratio is currently 50.00%.
In related news, Director Walter S. Woltosz sold 24,000 shares of the stock in a transaction dated Sunday, October 27th. The shares were sold at an average price of $33.45, for a total transaction of $802,800.00. Following the completion of the transaction, the director now owns 5,063,918 shares in the company, valued at $169,388,057.10. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last 90 days, insiders have sold 72,000 shares of company stock valued at $2,532,720. 31.57% of the stock is owned by company insiders.
SLP has been the topic of several research reports. Liberum Capital restated a “buy” rating on shares of Simulations Plus in a report on Tuesday, October 22nd. BidaskClub downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Zacks Investment Research upgraded shares of Simulations Plus from a “hold” rating to a “buy” rating and set a $38.00 target price for the company in a research note on Wednesday, October 30th. Finally, ValuEngine lowered shares of Simulations Plus from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $38.00.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Recommended Story: Sell-Side Analysts
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.